Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 38, Issue 9

Issues

How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and Transport

Christian Meisel / Ivar Roots / Ingolf Cascorbi / Ulrich Brinkmann / Jürgen Brockmöller
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2000.126

Abstract

Significant fractions of health budgets must be spent for treatment of drug side effects and for inefficient drug therapy. Hereditary variants in drug metabolizing enzymes, drug transporters, and drug targets are important determinants of drug response and toxicity and may therefore aid in selection and dosage of drugs. Today there is extensive knowledge of genetic polymorphisms of cytochrome P450 (CYP) enzymes 2A6, 2C9, 2C19, and 2D6; of phase-2 enzymes such as thiopurine S-methyltransferase; and more recently of drug transporters such as the MDR-1 gene-product P-glycoprotein, affecting a significant share of currently used drugs. However, application of pharmacogenetic knowledge to clinical routine is limited in current practice. To promote the application of pharmacogenetic knowledge in clinical routine, research on genotype-based dose adjustments is still necessary—as is the promotion of faster and cheaper genotype analyses. Furthermore, the benefits of CYP genotype-directed drug therapy should be evaluated in properly designed prospective studies. Once such steps have been successfully taken, drug therapy could well become more prevention-directed and patient-tailored than it is possible today, replacing the current “one drug in one dose for one disease” strategy by a more individualized approach.

About the article

Published Online: 2005-06-01

Published in Print: 2000-09-18


Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 38, Issue 9, Pages 869–876, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2000.126.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Christian Meisel, Thomas Gerloff, Julia Kirchheiner, Przemyslaw M. Mrozikiewicz, Przemyslaw Niewinski, Jürgen Brockmöller, and Ivar Roots
Journal of Molecular Medicine, 2003, Volume 81, Number 3, Page 154
[2]
Dorgival Caetano and Irina Piatkov
Personalized Medicine, 2016, Volume 13, Number 2, Page 113
[3]
Ivar Roots, Thomas Gerloff, Christian Meisel, Julia Kirchheiner, Mark Goldammer, Rolf Kaiser, Gabriele Laschinski, Jürgen Brockmöller, Ingolf Cascorbi, Ullrich Kleeberg, and Alfred G. Hildebrandt
Drug Metabolism Reviews, 2004, Volume 36, Number 3-4, Page 617
[4]
Janyce F Rogers, Anne N Nafziger, and Joseph S Bertino
The American Journal of Medicine, 2002, Volume 113, Number 9, Page 746
[5]
Bonny L Bukaveckas, Roland Valdes, and Mark W Linder
Journal of Cardiothoracic and Vascular Anesthesia, 2004, Volume 18, Number 3, Page 353
[6]
Matthew E Falagas and Drosos E Karageorgopoulos
The Lancet, 2010, Volume 375, Number 9710, Page 248
[7]
Russ B. Altman and Teri E. Klein
Annual Review of Pharmacology and Toxicology, 2002, Volume 42, Number 1, Page 113
[8]
Reinhold Kerb, Sven Hoffmeyer, and Ulrich Brinkmann
Pharmacogenomics, 2001, Volume 2, Number 1, Page 51
[9]
Hong-Guang Xie, Alastair JJ Wood, Richard B Kim, C Michael Stein, and Grant R Wilkinson
Pharmacogenomics, 2004, Volume 5, Number 3, Page 243
[10]
Thomas Dandekar and Rainer Sauerborn
Pharmacogenomics, 2002, Volume 3, Number 2, Page 245
[11]
Charles Dumontet and Mary Ann Jordan
Nature Reviews Drug Discovery, 2010, Volume 9, Number 10, Page 790
[12]
Fatima Vrtic, Walter E. Haefeli, Jürgen Drewe, Stephan Krähenbühl, and Markus Wenk
British Journal of Clinical Pharmacology, 2003, Volume 55, Number 2, Page 191
[13]
Hyun-Ju Kim, Seung Yeon Hwang, Ju-Ho Kim, Hye-Jung Park, Sang-Gyu Lee, Si-Woo Lee, Jong-Cheon Joo, and Yun-Kyung Kim
Evidence-Based Complementary and Alternative Medicine, 2009, Volume 6, Number s1, Page 73
[14]
Kun Tang, Soo-Mun Ngoi, Pai-Chung Gwee, John M. Z. Chua, Edmund J. D. Lee, Samuel S. Chong, and Caroline G. L. Lee
Pharmacogenetics, 2002, Volume 12, Number 6, Page 437
[15]
Regine Kollek, Jan van Aken, Günter Feuerstein, and Mechtild Schmedders
Public Health Genomics, 2006, Volume 9, Number 1, Page 50
[16]
Bertrand Rochat
Clinical Pharmacokinetics, 2005, Volume 44, Number 4, Page 349

Comments (0)

Please log in or register to comment.
Log in